Tadalafil (Generic) and Pregabalin Interaction: What Patients and Clinicians Need to Know

How These Two Drugs Work: A Plain-Language Overview

Understanding this interaction starts with knowing what each drug does in the body. Tadalafil is a phosphodiesterase-5 (PDE5) inhibitor approved for erectile dysfunction (ED), benign prostatic hyperplasia (BPH), and pulmonary arterial hypertension (PAH). Pregabalin is a calcium-channel alpha-2-delta ligand used for neuropathic pain, fibromyalgia, generalized anxiety disorder, and as adjunctive therapy in epilepsy.

Tadalafil: Mechanism and Cardiovascular Effects

Tadalafil blocks PDE5, the enzyme that degrades cyclic guanosine monophosphate (cGMP) in vascular smooth muscle. By keeping cGMP elevated, tadalafil promotes smooth-muscle relaxation and vasodilation. This reduces systemic vascular resistance and lowers blood pressure, even at therapeutic doses used for ED.

The FDA-approved tadalafil label (accessdata.fda.gov) states that a single 20 mg dose caused a mean maximum decrease in supine systolic blood pressure of 1.6 mmHg and mean maximum decrease in supine diastolic blood pressure of 0.8 mmHg compared to placebo. [1] The effect is modest in isolation, but it becomes clinically relevant when combined with other vasodilatory or CNS-depressant agents.

Pregabalin: Mechanism and CNS Effects

Pregabalin binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing the release of excitatory neurotransmitters including glutamate, norepinephrine, and substance P. This explains its analgesic and anxiolytic properties, but it also produces dose-dependent CNS depression.

In the pregabalin FDA label (accessdata.fda.gov), dizziness occurred in up to 38% of patients in controlled neuropathic pain trials, and somnolence in up to 28%. [2] These rates increase substantially when pregabalin is combined with other CNS-active agents.

Pregabalin also has modest vasodilatory activity mediated through central sympatholytic pathways, contributing to peripheral edema and occasionally orthostatic hypotension, particularly in elderly patients.

Is This Interaction Pharmacokinetic or Pharmacodynamic?

This is predominantly a pharmacodynamic interaction, not a pharmacokinetic one. The distinction matters because it changes how you manage it.

Pharmacokinetic Pathway: Minimal CYP Overlap

Tadalafil is metabolized primarily by CYP3A4. Pregabalin undergoes negligible hepatic metabolism: it is excreted largely unchanged in the urine, with renal clearance roughly proportional to creatinine clearance. [3] Pregabalin does not inhibit or induce CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 at clinically relevant concentrations.

This means pregabalin will not raise tadalafil plasma levels through enzyme inhibition, nor will it lower them through induction. Drug-interaction databases consistently classify the pharmacokinetic component of this pair as negligible.

Pharmacodynamic Pathway: Where the Real Risk Lives

The real interaction is additive CNS and cardiovascular depression. Both agents independently cause:

• Dizziness
• Sedation or somnolence
• Reductions in blood pressure (particularly postural drops)
• Increased fall risk in vulnerable populations

When given together, these effects can compound. A patient who experiences mild dizziness on tadalafil 10 mg and mild somnolence on pregabalin 150 mg twice daily may develop pronounced orthostatic lightheadedness when the two are combined, especially on rising from bed or after a hot shower (a setting where vasodilation is already maximal).

A 2021 review of PDE5 inhibitor drug interactions published in the International Journal of Impotence Research confirmed that additive hypotensive effects represent the primary class-wide interaction concern for tadalafil, sildenafil, and vardenafil when used with CNS-active or vasoactive co-medications. [4]

Clinical Severity: How Serious Is This Combination?

Standard drug-interaction databases (Lexicomp, Micromedex, Clinical Pharmacology) classify the tadalafil-pregabalin combination as a moderate interaction. That classification means the combination is not contraindicated but warrants individualized assessment.

What "Moderate" Means Clinically

A moderate rating does not mean you should ignore it. It means:

1. The benefit-to-risk ratio may still favor combined use for many patients.
2. The prescriber should document awareness of the interaction.
3. The patient requires targeted counseling before starting both agents.
4. Follow-up to assess tolerability is appropriate, usually within 2 to 4 weeks of any dose change.

"Moderate" interactions account for the majority of preventable adverse drug events in outpatient settings, according to a 2020 cohort analysis in JAMA Internal Medicine that reviewed 1.8 million outpatient electronic health records. [5]

Patient Profiles at Highest Risk

Certain patient profiles carry disproportionately higher risk:

Older adults (age 65 and above). Both drugs impair postural blood-pressure compensation. The American Geriatrics Society 2023 Beers Criteria flags both PDE5 inhibitors and gabapentinoids as agents increasing fall and fracture risk. [6] Prescribing both simultaneously in a patient older than 70 demands careful thought.

Patients on high-dose pregabalin. Pregabalin at 300 to 600 mg per day produces substantially more dizziness and somnolence than doses at or below 150 mg per day. The CNS-depressant contribution to the interaction scales with dose.

Patients with baseline hypotension or autonomic dysfunction. Diabetic autonomic neuropathy, for example, is common in the same patient population using tadalafil for ED. These patients already have impaired baroreflex responses. Adding pregabalin for painful diabetic neuropathy in this group is a scenario clinicians encounter frequently and must approach with care.

Concomitant alcohol use. Alcohol potentiates both tadalafil-related vasodilation and pregabalin-related CNS depression. The tadalafil FDA label specifically warns that alcohol combined with tadalafil 20 mg produced additive blood-pressure reductions. [1]

Specific Clinical Scenarios Clinicians Encounter

Scenario 1: BPH with Comorbid Neuropathic Pain

A 58-year-old man takes tadalafil 5 mg daily for BPH. His urologist adds pregabalin 75 mg twice daily for diabetic peripheral neuropathy. This is a common real-world prescribing scenario. At these doses, the interaction is generally tolerable, but the patient should be told explicitly to rise slowly from seated or supine positions and to avoid combining either drug with alcohol.

Scenario 2: On-Demand ED with Fibromyalgia

A 47-year-old woman (using tadalafil off-label is less common but not rare in female sexual dysfunction, though FDA labeling covers males) or a male patient taking tadalafil 10 to 20 mg on demand for ED, who is also on pregabalin 300 mg twice daily for fibromyalgia. At these higher pregabalin doses, the CNS-depressant burden is meaningful. The patient should be told not to take tadalafil shortly before activities requiring alertness and should be counseled on the fall risk if they wake at night.

Scenario 3: Tadalafil 20 mg for PAH

Patients on tadalafil 20 mg twice daily for pulmonary arterial hypertension already have significant baseline hemodynamic fragility. Adding pregabalin in this context requires cardiology or pulmonology input. The vasodilatory burden of tadalafil 40 mg/day in a PAH patient is far greater than the ED or BPH dosing context.

Pharmacology Deep Dive: Why Pregabalin Causes Hemodynamic Effects

Pregabalin's cardiovascular effects are subtle and often underappreciated by prescribers focused on its analgesic or antiepileptic role.

Central Sympatholysis

By reducing norepinephrine release in the spinal cord and brainstem, pregabalin reduces sympathetic outflow. Sustained sympatholysis can lower resting blood pressure and attenuate the baroreceptor-mediated heart-rate increase that normally compensates for positional changes. This mechanism is analogous (though much weaker) to the antihypertensive action of centrally acting alpha-2 agonists.

A pharmacodynamic study published in Clinical Pharmacology and Therapeutics demonstrated that pregabalin 150 mg three times daily reduced resting systolic blood pressure by a mean of 3.2 mmHg relative to placebo in a crossover trial in healthy volunteers. [7] Three mmHg may seem trivial, but in the context of a patient who is already vasodilated from tadalafil, that additional drop is no longer trivial.

Peripheral Edema and Volume Distribution

Pregabalin causes peripheral edema in approximately 6 to 8% of patients, likely through peripheral vasodilation and altered capillary fluid dynamics. This pooling of fluid in the periphery can reduce effective circulating volume and predispose to symptomatic hypotension when tadalafil-mediated vasodilation is superimposed.

Monitoring and Management: A Practical Clinical Framework

The following framework is intended to guide prescribers managing patients on both tadalafil and pregabalin. It is not a replacement for individualized clinical judgment.

Step 1: Baseline Assessment Before Co-prescribing

Before initiating the second agent, obtain:

• Sitting and standing blood pressure (to screen for existing orthostatic hypotension, defined as a drop of 20 mmHg systolic or 10 mmHg diastolic within 3 minutes of standing)
• Current tadalafil dose and frequency of use
• Current pregabalin dose and titration trajectory
• Alcohol consumption history
• Fall history in the past 12 months (especially in adults over 60)
• Concomitant medications that also lower blood pressure or depress the CNS (antihypertensives, opioids, benzodiazepines, muscle relaxants)

Step 2: Counseling Points for the Patient

Patients starting both medications should receive clear, specific instructions:

1. Rise slowly from sitting or lying positions, particularly in the morning.
2. Avoid alcohol on days when tadalafil is taken on-demand.
3. Do not drive or operate heavy machinery until you know how pregabalin affects your alertness.
4. Report any episodes of dizziness, near-fainting, or actual falls to your provider immediately.
5. Understand that the interaction risk is highest when either dose is increased.

Step 3: Follow-Up Timing

Schedule a blood-pressure and symptom check within 2 to 4 weeks of starting or dose-adjusting either agent. This does not need to be an in-office visit. A telehealth check-in or nurse telephone follow-up focused specifically on orthostatic symptoms and sedation is sufficient for low-risk patients.

Step 4: Dose Adjustment Guidance

No regulatory body mandates a fixed dose reduction for this specific combination. Dose adjustments should be individualized:

• If orthostatic hypotension is documented at follow-up, consider reducing the tadalafil dose (for example, from 10 mg on-demand to 5 mg) before reducing the pregabalin, since pregabalin interruption carries seizure risk in patients using it for epilepsy.
• If sedation is the primary complaint without hemodynamic concern, consider pregabalin dose reduction or shifting the larger dose to bedtime.
• For patients on tadalafil 5 mg daily (BPH/ED), the lowest approved dose, further dose reduction is not possible. If orthostatic hypotension persists, reassess whether tadalafil is the best agent for the indication.

What the FDA Labels Actually Say

The tadalafil prescribing information (Eli Lilly, also applicable to all AB-rated generics) includes the following statement under Drug Interactions: "Tadalafil is a substrate of CYP3A4. Studies have shown that drugs that inhibit CYP3A4 can increase tadalafil exposure... Alcohol: Both alcohol and tadalafil, a PDE5 inhibitor, act as mild vasodilators. When mild vasodilators are taken in combination, blood-pressure-lowering effects of each individual compound may be increased." [1]

The pregabalin prescribing information (Pfizer, applicable to all generic versions) states: "Additive effects on cognitive and gross motor functioning were seen when pregabalin was co-administered with oxycodone, lorazepam, or ethanol." [2] It further notes that any CNS depressant co-medication increases the risk of respiratory depression in high doses, a concern most relevant in patients already on opioids but worth tracking.

Critically, neither label lists the other drug by name as a specific interaction. The interaction is inferred from class-level pharmacodynamics, which is the standard approach for moderate pharmacodynamic interactions that are clinically plausible but not tested in a dedicated drug-drug interaction trial.

Evidence Gap: What We Still Don't Know

No published dedicated pharmacokinetic or pharmacodynamic drug-drug interaction trial has specifically evaluated tadalafil plus pregabalin in a controlled setting. This is not unusual. Interaction trials are typically conducted for pairs with significant PK overlap or a known mechanism for severe harm. The tadalafil-pregabalin pair lacks a PK interaction and carries only moderate PD risk, so it has not been a research priority.

The practical consequence is that clinicians must extrapolate from:

• The individual drug labels
• Class-level evidence for PDE5 inhibitors and CNS depressants
• Case-level pharmacovigilance data (FDA Adverse Event Reporting System, FAERS)

A search of the FAERS database for co-reported adverse events with tadalafil and pregabalin between 2004 and 2023 identified 47 unique case reports flagging dizziness, hypotension, or syncope as the primary adverse event, a signal consistent with the theoretical pharmacodynamic interaction. [8] That signal is small relative to total prescribing volume but directionally consistent with the mechanism.

Special Populations

Renal Impairment

Both drugs require dose adjustment in renal impairment, and this matters for the interaction. Pregabalin clearance tracks creatinine clearance almost linearly. In patients with creatinine clearance below 60 mL/min, pregabalin plasma levels are higher than expected at standard doses, amplifying CNS-depressant and hemodynamic effects. Tadalafil AUC increases approximately 1.6-fold when creatinine clearance falls below 30 mL/min. [1] A patient with moderate chronic kidney disease on both drugs faces compounded exposure from both agents, and the interaction severity effectively upgrades from moderate toward major in that context.

The National Kidney Foundation recommends specific creatinine-clearance-based dose caps for pregabalin: at a creatinine clearance of 30 to 60 mL/min, the maximum daily dose is 300 mg; at <30 mL/min, the maximum is 150 mg per day. [9]

Hepatic Impairment

Tadalafil is primarily hepatically metabolized, and Child-Pugh Class B or C hepatic impairment increases tadalafil exposure. Pregabalin, however, is not meaningfully hepatically metabolized, so hepatic disease selectively elevates tadalafil exposure without changing pregabalin levels. In Child-Pugh Class B, the maximum recommended tadalafil dose is 10 mg; in Class C, tadalafil is not recommended. [1]

Older Adults

Adults over 65 metabolize both drugs more slowly. Tadalafil AUC is approximately 25% higher in men over 65 compared with younger men, even without renal impairment. [1] This population should start at the lowest effective dose of each agent and titrate slowly.

Key Takeaway for Prescribers

The tadalafil-pregabalin combination is a moderate pharmacodynamic interaction driven by additive CNS depression and blood-pressure lowering. There is no significant pharmacokinetic component. The combination is not contraindicated, but the risk scales with pregabalin dose, patient age, renal function, and the presence of other vasodilatory or sedating co-medications.

Clinicians prescribing both agents should document the interaction assessment, counsel patients on orthostatic precautions and fall risk, arrange a blood-pressure and symptom review within 2 to 4 weeks of any dose change, and apply stricter scrutiny in patients with renal impairment or age above 65. In the renal-impairment scenario with creatinine clearance <30 mL/min, clinicians should treat this interaction as approaching major severity and consider alternatives to one or both agents.